BIOMARKER:

RET mutation

Entrez ID:

Related biomarkers:

‹

›

RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: A1 - Approval	selpercatinib Sensitive: A1 - Approval
RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: A1 - Approval	pralsetinib Sensitive: A1 - Approval
RET mutation RET mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	RET mutation RET mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	selpercatinib Sensitive: A2 - Guideline	selpercatinib Sensitive: A2 - Guideline
RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	TPX-0046 Sensitive: C2 – Inclusion Criteria	TPX-0046 Sensitive: C2 – Inclusion Criteria
RET mutation RET mutation	Non Small Cell Lung Cancer NSCLC	RET mutation RET mutation	Non Small Cell Lung Cancer NSCLC	TPX-0046 Sensitive: C2 – Inclusion Criteria	TPX-0046 Sensitive: C2 – Inclusion Criteria
RET mutation RET mutation	Non Small Cell Lung Cancer NSCLC	RET mutation RET mutation	Non Small Cell Lung Cancer NSCLC	BOS-172738 Sensitive: C2 – Inclusion Criteria	BOS-172738 Sensitive: C2 – Inclusion Criteria
RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	BOS-172738 Sensitive: C2 – Inclusion Criteria	BOS-172738 Sensitive: C2 – Inclusion Criteria
RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RET inhibitor Sensitive: C3 – Early Trials	RET inhibitor Sensitive: C3 – Early Trials
RET mutation RET mutation	Non Small Cell Lung Cancer NSCLC	RET mutation RET mutation	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: C3 – Early Trials	nivolumab + ipilimumab Sensitive: C3 – Early Trials
RET mutation RET mutation	Melanoma Melanoma	RET mutation RET mutation	Melanoma Melanoma	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
RET mutation RET mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	RET mutation RET mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	LDD-2633 Sensitive: D – Preclinical	LDD-2633 Sensitive: D – Preclinical
RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical	RTB101 + RAF265 Sensitive: D – Preclinical
RET mutation RET mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	RET mutation RET mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	CB-228 + AST-487 Sensitive: D – Preclinical	CB-228 + AST-487 Sensitive: D – Preclinical
RET mutation RET mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	RET mutation RET mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	AST-487 Sensitive: D – Preclinical	AST-487 Sensitive: D – Preclinical